In a large clinical study called AIM-HIGH (for Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes), researchers evaluated the impact of extended release niacin (vitamin B3) on blood lipids. In a previous review of patients in this AIM-HIGH trial, niacin showed no benefit to statin-treated patients when analyzed as a whole group. However, in a subsequent analysis, niacin appeared to benefit patients who had high triglycerides (over 200 mg/dL) and very low HDL (less than 32 mg/dL). In this analysis, the authors sought to find out the specific changes in lipoproteins that conferred the benefit seen in the subset of patients with high triglycerides and low HDL.
Lipoprotein particles were analyzed on 2457 participants in the AIM-HIGH trial to establish baseline values and again after one year of treatment with extended release niacin. Those taking niacin had higher HDL after one year (a good outcome since HDL is protective). In addition, the analysis of lipoprotein subfractions showed that this benefit – specific to people with high triglycerides and low HDL – was likely due to the reduction in remnant lipoproteins, also known as RLP.
This unique lipoprotein is particularly harmful because unlike LDL particles, which have to undergo oxidation before they can be taken into the arterial intima, RLP lipoproteins can be readily transformed into foam cells which is what comprises arterial plaque. In fact, RLP is one of the four major risk factors cited by the National Cholesterol Education Program that contribute to heart disease. This paper suggests that the benefit seen in patients taking niacin was due to a reduction in this particularly harmful lipoprotein called RLP.
Micronutrients are involved in the body’s countless metabolic reactions; therefore, a single deficiency can affect cardiac and metabolic health. Regardless of your medical history and current health, micronutrient testing in combination with our CardioMetabolic evaluation can help your health care provider identify your risk and design a personalized treatment plan for you.
(Journal of Clinical Lipidology, May 2018)
SpectraCell Laboratories has officially been granted a license to provide its Lipoprotein Particle Profile™ (LPP™) test, which assesses cardiovascular risk, to New York state physicians and patients. The recently patented LPP™ test has been commercially available to the other 49 states since 2006.
SpectraCell began the process of acquiring a licensure in 2008 with an application submission the state of New York. The laboratory underwent an initial inspection by the New York State Department of Health in late 2009 followed by extensive documentation validating the LPP™ procedure, which is standard protocol required of all diagnostic laboratories. A final inspection in December 2010 concluded the evidentiary process, proving the LPP™ technology is valid, accurate and reproducible.
“Acquiring our New York license allows us to serve the largest metropolitan area in the country,” states Dr. Fred Crawford, PhD, VP of Operations and Laboratory Director at SpectraCell Labs. “In fact, many physicians in the state of New York have wanted to implement the LPP™ test in their practice but were unable to do so until now. Plus, we recently streamlined our LPP™ report using feedback from existing LPP™ clients, making it easier than ever for physicians to translate LPP™ results into clinical decisions.”
New York represents a large market for laboratory testing. According to a CNN report, approximately 40,000 physicians practice within a 30 mile radius of New York City, in contrast to a national average of about 8000 physicians for other American cities.
After visiting the laboratory and reviewing the testing protocol, Dr. Robert Rej, Director of Chemistry for the State of New York Department of Health recommended the permit be approved for SpectraCell’s LPP™ testing. The license also allows SpectraCell to add FDA approved chemistry procedures to New York clients. Their first addition will be LpPLA2 testing (lipoprotein-associated phospholipase A2) which measures a specific enzyme linked to thrombosis (blood clots), indicating a higher risk of heart attack or stroke.
Just a few months ago, SpectraCell Laboratories was awarded a patent on their Lipoprotein Particle Profile™ (LPP™) test, which measures both the size and number of lipoproteins rather than the cholesterol contained within them. In recent years, more doctors have seen standard cholesterol tests label a patient “normal” when in reality their risk for heart disease is quite high.
In fact, The National Cholesterol Education Program (NCEP) acknowledges that 50% of people that have heart attacks have “normal” cholesterol – that is, cholesterol below 200 mg/dL. The LPP™ test allows physicians to stratify risk more accurately, thus prescribing therapies that will be the most effective, depending on their patients’specific lipid profile.
NCEP recognizes four risk factors that are not measured with routine cholesterol testing but are all measured by the LPP™ test:
- RLP – (remnant lipoprotein) more easily converted into arterial plaque than other lipoproteins
- Lp(a) – a dangerous lipoprotein that contributes to clot formation
- HDL2b – a type of HDL that indicates how well cholesterol is being cleared from your system
- Small, dense LDL – easily penetrates vascular wall, causing damage and plaque
The LPP™ is part of the trend toward more individualized medicine. The LPP™ test, which is done on a fasting blood sample, is usually covered by insurance. Results typically take 3-5 days.
Stop by our booths in New York City!
We will be at Booth #28 at the National Lipid Association (NLA) Scientific Session (May 19-22, 2011) and Booth #435 at Pri-Med (June 16-18, 2011)!
Houston, TX- January 28, 2011. SpectraCell Laboratories has recently been awarded a patent on their Lipoprotein Particle Profile™ (LPP™) test which is used to measure cardiovascular risk. The LPP™ has been commercially available since 2006, and is a type of advanced cholesterol test that measures lipoprotein subgroups. The LPP™ gives more accurate estimation of cardiovascular risk compared to a routine cholesterol test.
The patent was awarded for use of a “Method for Analyzing Blood for Lipoprotein Components.” Specifically, the LPP™ test utilizes a patented analytical ultracentrifugation method for separating lipoprotein subclasses. This separation method for LPP™ originated at Texas A & M University and was further developed by Dr. Jan Troup, the inventor of LPP™ technology, who is also a member of SpectraCell's scientific staff.
“The LPP™ generally doesn’t cost the patient any more than a standard cholesterol test, but it gives the doctor much more relevant and accurate information.” states Dr. Jan Troup, PhD, and Director of Lipid Science for SpectraCell Laboratories. “Different lipoproteins respond differently to therapy, whether it is statins, fish oils or niacin, for example. The LPP™ enables the doctor to treat appropriately.”
In recent years, the medical community has discovered that, beyond “standard” cholesterol tests, an independent factor for heart disease can be determined by measuring the density and number of lipoprotein particles, to which cholesterol is attached. Patients with a normal cholesterol value, but abnormal particle sizes or numbers, can be at serious risk for cardiovascular disease.
In fact, The National Cholesterol Education Program (NCEP) acknowledges that 50% of people that have heart attacks have “normal” cholesterol – that is, cholesterol below 200 mg/dL. NCEP recognizes four risk factors that are not measured with routine cholesterol testing but are all measured by the LPP™ test:
1. RLP – (remnant lipoprotein) more easily converted into arterial plaque than other lipoproteins
2. Lp(a) – a dangerous lipoprotein that contributes to clot formation
3. HDL2b – a type of HDL that indicates how well cholesterol is being cleared from your system
4. Small, dense LDL – easily penetrates vascular wall, causing damage and plaque
The main reason to know NCEP risk factors are that specific lipoproteins respond to specific therapies very differently. The LPP™ is part of the trend toward more individualized medicine. The LPP™ test, which is done on a fasting blood sample, is usually covered by insurance. Results typically take 3-5 days.
For more information, go to www.spectracell.com
contact Dr. Jan Troup, PhD – Director of Lipid Science at 800-227-5227
Topics: SpectraCell, lipoprotein particle profile, LPP, Cholesterol, Cardiovascular Health, diagnostic tools, Heart Disease, Lp(a), Lipoprotein Particles, NCEP, RLP, LDL and HDL, Patent, Dr. Jan Troup